India and Uzbekistan on Monday launched a pharmaceutical and nutraceutical trade corridor for linking Indian manufacturers with markets across the Commonwealth of Independent States (CIS) and the wider Eurasian region, as per news reports.
The healthcare and supplements opportunity across these markets is estimated at about $7-10 billion.
The arrangement has been developed with the involvement of Uzbekistan’s Ministry of Health, Nutrify Today and Pharma Eurasia.
The corridor is intended to provide a formal structure for companies seeking to supply medicines and health supplements across CIS countries.
Demand for dietary supplements and preventive healthcare products has been rising in several CIS markets. Vitamins, herbal supplements, and functional nutrition products have seen wider availability through organised pharmacy networks.
The CIS dietary supplements market is estimated at more than $5.8 billion a year. When broader pharmaceutical and nutraceutical demand across Eurasia is included, the potential market size is estimated at $7-10 billion.
The initiative is expected to support regulatory coordination and trade processes between companies and authorities in the participating regions. It is intended to help manufacturers manage regulatory approvals, documentation, and distribution requirements.
The framework may also allow Indian manufacturers to work with distributors and companies across Eurasian markets. Partnerships, supply agreements, and contract manufacturing arrangements may be explored through the platform.
Uzbekistan has introduced several policy changes aimed at developing its pharmaceutical sector. These include the creation of pharmaceutical parks and adjustments to regulatory processes related to manufacturing and approvals.
Authorities have also introduced investment facilitation programmes to attract international manufacturers and contract development partners.
As per reports, Uzbekistan’s location between India, Russia and Central Asia places it along important regional trade routes. This position allows companies operating in the country to reach multiple CIS markets through existing logistics links.
Industrial clusters and infrastructure projects are also being developed to support pharmaceutical manufacturing and exports.
Commercial discussions linked to the corridor are expected to take place at Pharma Eurasia 2026. The event is scheduled to be held in Tashkent from May 20 to May 22.
Manufacturers, ingredient suppliers, contract manufacturers, distributors and regulatory representatives from across Eurasia are expected to participate.
The initiative connects Indian manufacturers with distributors and buyers across CIS markets. It is expected to facilitate trade in medicines and health supplements across the region.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Mar 10, 2026, 10:16 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
EN